Simplex Trading
BMRN icon

Simplex Trading’s BioMarin Pharmaceuticals BMRN Stock Holding History

Simplex Trading’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$469K Sell
8,300
-35,300
-81% -$2.06M ﹤0.01% 3339
2025
Q4 		$2.59M Sell
43,600
-18,600
-30% -$1.01M ﹤0.01% 1770
2025
Q3 		$3.37M Buy
62,200
+19,600
+46% +$1.12M ﹤0.01% 1824
2025
Q2 		$2.34M Sell
42,600
-13,000
-23% -$766K ﹤0.01% 1963
2025
Q1 		$3.93M Sell
55,600
-48,800
-47% -$3.28M ﹤0.01% 1461
2024
Q4 		$6.86M Sell
104,400
-19,400
-16% -$1.3M ﹤0.01% 1255
2024
Q3 		$8.7M Buy
123,800
+29,200
+31% +$2.44M 0.01% 1126
2024
Q2 		$7.79M Buy
94,600
+23,500
+33% +$1.96M ﹤0.01% 1173
2024
Q1 		$6.21M Sell
71,100
-5,400
-7% -$483K ﹤0.01% 1443
2023
Q4 		$7.38M Buy
76,500
+35,400
+86% +$3.13M ﹤0.01% 1293
2023
Q3 		$3.64M Sell
41,100
-28,100
-41% -$2.5M ﹤0.01% 1566
2023
Q2 		$6M Buy
69,200
+20,000
+41% +$1.88M ﹤0.01% 1194
2023
Q1 		$4.78M Sell
49,200
-26,300
-35% -$2.73M ﹤0.01% 1329
2022
Q4 		$7.81M Buy
75,500
+10,500
+16% +$986K 0.01% 966
2022
Q3 		$5.51M Buy
65,000
+9,000
+16% +$801K 0.01% 1133
2022
Q2 		$4.64M Buy
56,000
+35,600
+175% +$2.83M ﹤0.01% 1196
2022
Q1 		$1.57M Sell
20,400
-33,500
-62% -$2.8M ﹤0.01% 2355
2021
Q4 		$4.76M Sell
53,900
-40,600
-43% -$3.35M ﹤0.01% 1243
2021
Q3 		$7.93M Hold
94,500
– – 0.01% 859
2021
Q2 		$7.88M Buy
94,500
+93,673
+11,327% +$7.43M 0.01% 850
2021
Q1 		$6.24M Buy
827
+185
+29% +$15.1K 0.01% 670
2020
Q4 		$5.63M Sell
642
-164
-20% -$13K 0.01% 910
2020
Q3 		$6.13M Buy
806
+75
+10% +$7.59K 0.01% 739
2020
Q2 		$9.02M Buy
731
+34
+5% +$3.38K 0.01% 559
2020
Q1 		$5.89M Buy
697
+228
+49% +$19.6K 0.01% 620
2019
Q4 		$3.96M Buy
469
+308
+191% +$23.3K 0.01% 950
2019
Q3 		$1.08M Sell
161
-114
-41% -$8.78K ﹤0.01% 1861
2019
Q2 		$2.35M Sell
275
-154
-36% -$13.2K 0.01% 1187
2019
Q1 		$3.81M Buy
429
+238
+125% +$22.1K 0.01% 862
2018
Q4 		$1.63M Sell
191
-98
-34% -$9.32K ﹤0.01% 1235
2018
Q3 		$2.8M Hold
289
– – 0.01% 985
2018
Q2 		$2.72M Buy
289
+190
+192% +$16.6K 0.01% 925
2018
Q1 		$50K Sell
99
-344
-78% -$29.5K ﹤0.01% 2434
2017
Q4 		$79K Buy
443
+241
+119% +$21K ﹤0.01% 2004
2017
Q3 		$32K Sell
202
-38
-16% -$3.36K ﹤0.01% 2710
2017
Q2 		$92K Buy
240
+73
+44% +$6.64K ﹤0.01% 1819
2017
Q1 		$39K Sell
167
-237
-59% -$21.1K ﹤0.01% 2590
2016
Q4 		$225K Buy
404
+64
+19% +$5.5K 0.01% 968
2016
Q3 		$106K Buy
340
+80
+31% +$7.53K 0.01% 1483
2016
Q2 		$298K Buy
260
+139
+115% +$11.8K 0.02% 775
2016
Q1 		$170K Sell
121
-2
-2% -$163 0.01% 974
2015
Q4 		$49K Sell
123
-11
-8% -$1.15K ﹤0.01% 1930
2015
Q3 		$326K Buy
134
+1
+0.8% +$134 0.02% 637
2015
Q2 		$58K Buy
133
+45
+51% +$5.58K ﹤0.01% 1584
2015
Q1 		$27K Buy
88
+40
+83% +$4.24K ﹤0.01% 2068
2014
Q4 		$2K Buy
+48
New +$3.99K ﹤0.01% 3678

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Simplex Trading's BMRN Position: Q4 2025 in Review

Simplex Trading sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 23,096 shares — an estimated $1.26M sold.

Simplex Trading first reported a position in BMRN in Q3 2015 and held it in 33 quarters. The position peaked at $3.17M in Q4 2024. 538 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

  • Simplex Trading reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Simplex Trading sold 23,096 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $1.26M.
  • Simplex Trading first reported a position in BioMarin Pharmaceuticals in Q3 2015 and held it in 33 quarters.
  • Simplex Trading's BioMarin Pharmaceuticals position peaked at $3.17M in Q4 2024.
  • 538 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Simplex Trading's 13F filing for Q4 2025, filed 11 Feb 2026.